CIK 0001850902 · In Vitro & In Vivo Diagnostic Substances (SIC 2835) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Revenue (USD) | 40.5 M | 36.7 M | 41.4 M |
| Net income (USD) | -17.3 M | -36.8 M | -47.5 M |
| Diluted EPS (USD/shares) | -0.32 | -1.16 | -1.69 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-20 | 424B5 | 424B5 | |
| 2026-08-06 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-05 | 8-K | 8-K items 2.02,9.01 | 2026-08-05 |
| 2026-07-16 | 4 | PRIMARY DOCUMENT | 2026-07-14 |
| 2026-06-02 | 4 | PRIMARY DOCUMENT | 2026-06-01 |
| 2026-06-02 | 4 | PRIMARY DOCUMENT | 2026-06-01 |
| 2026-06-02 | 4 | PRIMARY DOCUMENT | 2026-06-01 |
| 2026-06-01 | 8-K | 8-K items 5.02,5.07,9.01 | 2026-05-27 |
| 2026-05-07 | 10-Q | 10-Q | 2026-03-31 |
| 2026-05-06 | 8-K | 8-K items 2.02,5.05,9.01 | 2026-05-04 |
| 2026-04-21 | ARS | ARS | 2025-12-31 |
| 2026-04-21 | DEFA14A | DEFA14A | |
| 2026-04-21 | DEF 14A | DEF 14A | 2026-04-21 |
| 2026-03-09 | 4 | PRIMARY DOCUMENT | 2026-02-15 |
| 2026-03-09 | 4 | PRIMARY DOCUMENT | 2026-02-15 |
| 2026-03-09 | 4 | PRIMARY DOCUMENT | 2026-02-15 |
| 2026-03-02 | 10-K | 10-K | 2025-12-31 |
| 2026-02-26 | 8-K | 8-K items 2.02,9.01 | 2026-02-26 |
| 2025-11-07 | 10-Q | 10-Q | 2025-09-30 |
| 2025-11-06 | 8-K | 8-K items 2.02,9.01 | 2025-11-06 |
| 2025-08-08 | 10-Q | 10-Q | 2025-06-30 |
| 2025-08-07 | 8-K | 8-K items 2.02,9.01 | 2025-08-07 |
| 2025-07-16 | EFFECT | EFFECT items ,, | |
| 2025-07-14 | CORRESP | CORRESP | |
| 2025-07-14 | UPLOAD | UPLOAD |
Forms on file (last 1,000): 4 74, 8-K 38, 10-Q 16, 3 15, CORRESP 8, UPLOAD 6, DEF 14A 5, 10-K 5. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=TKNO (0.002 USD), /gw/filings/filings?ticker=TKNO&form=8-K, /gw/filings/facts?ticker=TKNO&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange